Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-08-11
Stuelpnagel John R Files 10x Genomics (TXG) Form 4 - August 11, 2026
Stuelpnagel John R sold 20.0K TXG shares worth $1.2M in this Form 4 filing, reported to the SEC on 2026-08-11.
- Insider
- Stuelpnagel John R
- Issuer
- 10x Genomics Inc. TXG · NASDAQ
- Filed
- Period
- 2026-08-11
- Accession
- 0001610717-26-000358
- Source
- Official filing on sec.gov ↗
Transactions (2)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Stuelpnagel John R | 2026-08-11 | Sell | 17.0K | $57.58 | $978.9K | Direct |
| Stuelpnagel John R | 2026-08-11 | Sell | 3.0K | $58.73 | $176.2K | Direct |
| Net change | −20.0K | −$1.2M | ||||
About 10x Genomics Inc.
10x Genomics Inc. is a biotechnology company known for developing advanced genomic analysis technologies designed to power breakthroughs in biological research. The primary purpose of 10x Genomics is to enhance the understanding of complex biological systems by providing tools that offer insights into cellular and molecular structures at unprecedented resolutions. The company's products include innovative single-cell and spatial gene expression platforms, which are instrumental in studying genetic variations, gene expression, and complex biological phenomena across numerous sectors. Notable for its impact on life sciences and healthcare industries, 10x Genomics serves researchers in fields such as oncology, immunology, and neuroscience, among others, enabling them to explore genetic foundations of health and disease more deeply. Headquartered in Pleasanton, California, 10x Genomics plays a significant role in facilitating scientific advancements and accelerates discovery in translational and clinical research settings, contributing to the broader pursuit of personalized medicine and novel therapeutic strategies.
Track TXG insider activity
Get alerted when 10x Genomics Inc. executives buy or sell their shares.